XTL Biopharmaceuticals Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on June 13, 2025, by XTL Biopharmaceuticals Ltd., a foreign private issuer based in Ramat Gan, Israel, serves to notify shareholders of an upcoming Annual and Extraordinary General Meeting of Shareholders. The filing does not contain financial results or operational updates for a specific reporting period but rather provides logistical details for the shareholder meeting scheduled for July 21, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice regarding a shareholder meeting and does not include financial statements or performance metrics.
Material Changes
No material changes to financial performance or operations are reported in this filing. The primary event is the scheduling of the Annual and Extraordinary General Meeting of Shareholders.
Guidance, Outlook, and Management Commentary
Management has announced the following details regarding the shareholder meeting:
- Date and Time: July 21, 2025, at 4:00 p.m. (Israel time).
- Location: Offices of Doron Tikotzky Kantor Gutman & Amit Gross., 7 Metsada St., B.S.R Tower 4, 33 Floor, Bnei Brak, Israel.
- Voting Procedures: Shareholders may vote in person or by proxy. The filing includes a Notice and Proxy Statement (Exhibit 99.1), a Proxy Card for ordinary share holders (Exhibit 99.2), and a Voting Instruction Card for American Depositary Share holders (Exhibit 99.3).
The filing does not contain specific guidance, outlook, risk factors, or contingencies beyond the standard procedural information for the meeting.
Key Facts for Investor Verification
- Verify the specific proposals to be voted upon in the attached Notice and Proxy Statement (Exhibit 99.1).
- Confirm the deadline for submitting proxy cards or voting instruction cards to ensure participation.
- Check for any subsequent filings that may contain the financial results or operational updates expected at the Annual General Meeting.